BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernández-Pedro NY, Rangel-López E, Vargas Félix G, Pineda B, Sotelo J. An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis 2013;2013:716813. [PMID: 24294521 DOI: 10.1155/2013/716813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yi X, Manickam DS, Brynskikh A, Kabanov AV. Agile delivery of protein therapeutics to CNS. J Control Release 2014;190:637-63. [PMID: 24956489 DOI: 10.1016/j.jconrel.2014.06.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
2 Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest 2016;96:137-50. [PMID: 26641068 DOI: 10.1038/labinvest.2015.140] [Cited by in Crossref: 117] [Cited by in F6Publishing: 118] [Article Influence: 19.5] [Reference Citation Analysis]
3 Yadav M, Khandelwal R, Mudgal U, Srinitha S, Khandekar N, Nayarisseri A, Vuree S, Singh SK. Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach. Asian Pac J Cancer Prev 2019;20:2681-92. [PMID: 31554364 DOI: 10.31557/APJCP.2019.20.9.2681] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jovčevska I, Zupanec N, Urlep Ž, Vranič A, Matos B, Stokin CL, Muyldermans S, Myers MP, Buzdin AA, Petrov I, Komel R. Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget 2017;8:44141-58. [PMID: 28498803 DOI: 10.18632/oncotarget.17390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
5 Hammarström LG, Harmel RK, Granath M, Ringom R, Gravenfors Y, Färnegårdh K, Svensson PH, Wennman D, Lundin G, Roddis Y, Kitambi SS, Bernlind A, Lehmann F, Ernfors P. The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features. J Med Chem 2016;59:8577-92. [PMID: 27607569 DOI: 10.1021/acs.jmedchem.6b01009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
6 Luiz MT, Delello Di Filippo L, Tofani LB, de Araújo JTC, Dutra JAP, Marchetti JM, Chorilli M. Highlights in targeted nanoparticles as a delivery strategy for glioma treatment. Int J Pharm 2021;604:120758. [PMID: 34090991 DOI: 10.1016/j.ijpharm.2021.120758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci 2018;8:E15. [PMID: 29337870 DOI: 10.3390/brainsci8010015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 19.0] [Reference Citation Analysis]
8 Zhu S, Liu Y, Wang PC, Gu X, Shan L. Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int 2017;2017:7929286. [PMID: 28752098 DOI: 10.1155/2017/7929286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Nadeem Abbas M, Kausar S, Wang F, Zhao Y, Cui H. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Cells 2019;8:E350. [PMID: 31013819 DOI: 10.3390/cells8040350] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
10 Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf 2017;16:277-87. [PMID: 27989218 DOI: 10.1080/14740338.2017.1273898] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Ellwanger K, Reusch U, Fucek I, Knackmuss S, Weichel M, Gantke T, Molkenthin V, Zhukovsky EA, Tesar M, Treder M. Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. Front Oncol 2017;7:100. [PMID: 28596941 DOI: 10.3389/fonc.2017.00100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jovčevska I, Zupanec N, Kočevar N, Cesselli D, Podergajs N, Stokin CL, Myers MP, Muyldermans S, Ghassabeh GH, Motaln H, Ruaro ME, Bourkoula E, Turnšek TL, Komel R. TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS One 2014;9:e113688. [PMID: 25419715 DOI: 10.1371/journal.pone.0113688] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hicks MJ, Chiuchiolo MJ, Ballon D, Dyke JP, Aronowitz E, Funato K, Tabar V, Havlicek D, Fan F, Sondhi D, Kaminsky SM, Crystal RG. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS One 2016;11:e0162978. [PMID: 27711187 DOI: 10.1371/journal.pone.0162978] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ge J, Li L, Jin Q, Liu YC, Zhao L, Song HH. Functional IRGM polymorphism is associated with language impairment in glioma and upregulates cytokine expressions. Tumour Biol 2014;35:8343-8. [PMID: 24859836 DOI: 10.1007/s13277-014-2091-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]